Today we are discussing the management of patients with chronic lymphocytic leukemia (CLL), including incorporating the newest approved therapies for CLL: duvelisib and venetoclax.
We are joined by Dr. Ian Flinn, a hematologist/oncologist and the director of the Blood Cancer Research Program at Sarah Cannon Research Institute in Tennessee. Dr. Flinn treats patients with CLL and has taken part in many clinical trials of agents in development for the disease.
Transcript...
Typo in regard to Obinituzumab---it is anti CD-20 (not 28). Always the editor...
I think he must mean the side effect of splitting nails is not as threatening as other side effects--it seems to be quite important from our posts.
Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax Dr. Neil Kay: CLL Society Webinar, Just Diagnosed: What Do I Need to Know? 
CLL, Ibrutinib side effects clarified, antibiotic side effects
Is low IgM a side-effect of CLL drug treatment? 
CLL and covid vaccine - efficacy and side effects?
